Abbott Laboratories Stock News

All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning school earning $1 million from Abbott for student or community health Abbott is releasing exclusive, limited-edition Homefield designed T-shirts for each Big Ten school. Be among the first to recei...

Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.

Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter Abbott's long-term moat. As a dividend aristocrat, its fundamental and valuation risks are better gauged by its dividend payouts than accounting EPS.

Priorities change as you enter new seasons of life. That's especially true for your retirement years.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Any company that can pay and raise its dividends over long periods almost certainly has strong underlying operations. So, corporations of this caliber can offer a lot more than just passive income.

Sufficient earnings growth to continually increase dividends at a comfortably low payout  ratio that also accommodates expansion capex is an excellent signal for strong upside potential.

Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 2025, with an average growth rate of 4.92% and more increases expected, signaling ongoing income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, ha...